Theratechnologies Inc.

Toronto Stock Exchange TH.TO

Theratechnologies Inc. Shares (Diluted, Weighted) for the year ending November 30, 2023: 26,332,429

Theratechnologies Inc. Shares (Diluted, Weighted) is 26,332,429 for the year ending November 30, 2023, a -72.36% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • Theratechnologies Inc. Shares (Diluted, Weighted) for the year ending November 30, 2022 was 95,253,348, a 3.14% change year over year.
  • Theratechnologies Inc. Shares (Diluted, Weighted) for the year ending November 30, 2021 was 92,350,198, a 19.95% change year over year.
  • Theratechnologies Inc. Shares (Diluted, Weighted) for the year ending November 30, 2020 was 76,991,635, a 0.08% change year over year.
  • Theratechnologies Inc. Shares (Diluted, Weighted) for the year ending November 30, 2019 was 76,928,287, a 1.30% change year over year.
Key data
Date Shares (Diluted, Weighted) Revenue Cost of Revenue Gross Profit
Market news
SV Wall Street
Toronto Stock Exchange: TH.TO

Theratechnologies Inc.

CEO Mr. Paul Lévesque
IPO Date Aug. 6, 1996
Location Canada
Headquarters 2015 Peel Street
Employees 103
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines
Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

StockViz Staff

February 6, 2025

Any question? Send us an email